Floatz logo

Cavrotolimod

Advanced or Metastatic Merkel Cell Carcinoma

Exicure, Inc.nucleic_acidPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

46 Active assets in the Advanced or Metastatic Merkel Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 2/3BB
Atezolizumab
Ariceum Therapeutics GmbH
Phase 2B
Durvalumab
Ariceum Therapeutics GmbH
Phase 2B
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

Cavrotolimod is also rated in:

skin squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
metastatic melanomaDormant
CCC
Indicative ·
48 / 100
View asset →
head and neck squamous cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →